As temperatures drop and respiratory illnesses begin to climb, health officials are urging the public to prioritize their annual immunizations. This year, the conversation is dominated by the arrival of a specific strain known as H3N2 Subclade K—more colloquially termed the “super-k” flu—which has already contributed to an unusually intense season in several parts of the world.
For most people, the priority is simply getting a flu vaccine this year and the ‘super-k’ flu protection it provides. While the name may sound alarming, medical experts emphasize that the current vaccine formulations are specifically updated to counter this variant. Vaccination remains the most reliable method to prevent severe complications and reduce the burden on hospital systems during the winter peak.
The arrival of “super-k” follows a period of significant instability in global respiratory patterns. Since the COVID-19 pandemic, the predictable “winter peak” of influenza has shifted, leading to more erratic timing and unpredictable surges. In New Zealand, for instance, flu cases in both 2024 and 2025 saw later-than-usual peaks toward the end of August, complicating the timing for those seeking protection.
According to data from PHF Science, the impact of vaccination is substantial; in 2025, individuals who were vaccinated had approximately a 69 percent lower chance of being infected compared to those who were not.
The Science Behind the ‘Super-K’ Strain
The H3N2 Subclade K is not a brand-new virus, but rather a mutation of the existing H3N2 influenza A virus. Specifically, mutations in one of its key proteins have altered how the virus behaves, and spreads. According to Australia’s science agency, CSIRO, this strain “has spread earlier and faster than typical seasonal influenza.”
The strain gained notoriety after hitting the United Kingdom last December, where it led to record hospitalizations. The NHS’s national medical director described the situation as a “worst-case scenario for this time of year.” However, CSIRO notes that the current best evidence suggests subclade K does not necessarily cause more severe disease in the individual, but rather spreads more efficiently through populations.
Medical professionals note that the Southern Hemisphere has a distinct advantage this year. Dr. Joan Ingram, a medical advisor for the Immunisation Advisory Centre at the University of Auckland, stated that “one of the strains in each vaccine is expected to provide protection against the K variant and was not included in the northern hemisphere vaccines.” This suggests that those in the Southern Hemisphere may have better protection against this specific mutation than those in the North.
Comparing Vaccine Options: Funded vs. Enhanced
Not all flu vaccines are identical. While the primary goal is to trigger an immune response against the most likely circulating strains, the technology used to create the vaccine can vary. In New Zealand, the government funds a specific vaccine for eligible groups, but other options are available for those willing to pay a premium.
The funded vaccine, Influvac Tetra, is an egg-based vaccine. While highly effective, some patients may opt for cell-based alternatives like Flucelvax, which uses cultured mammalian cells. Dr. Ingram notes that cell-based vaccines can be more effective in some seasons, with some data showing up to 20 percent more effectiveness in children and adults under 65 during certain Northern Hemisphere seasons.
For the elderly, “enhanced” vaccines are often recommended. Fluad, for example, contains an adjuvant—an ingredient designed to “kick the immune system along to produce a stronger response.” This is particularly beneficial for those aged 75 and older or those with multiple comorbidities, though it is not currently funded for the general 65+ population in New Zealand.
| Vaccine Type | Technology | Primary Benefit | Funding Status (NZ) |
|---|---|---|---|
| Influvac Tetra | Egg-based | Broad seasonal protection | Funded for eligible groups |
| Flucelvax | Cell-based | Potentially higher efficacy | Unfunded |
| Fluad | Adjuvanted | Stronger response for 75+ | Unfunded |
| Fluzone | Egg-based | Similar to Influvac Tetra | Unfunded |
Navigating Eligibility and Access
Public health goals this year are focused on protecting the most vulnerable. In New Zealand, the target is to vaccinate 75 percent of the population over 65. However, uptake has lagged; last year, only about 60 percent of this group received the shot, suggesting that barriers beyond cost—such as access or vaccine hesitancy—persist.
The flu vaccine is provided free of charge to those at the highest risk of severe illness. This includes:
- People aged 65 years and over.
- Pregnant individuals.
- People aged 6 months and over with long-term medical conditions such as asthma, diabetes, or heart disease.
- Children aged 4 and under with a history of significant respiratory illness or hospitalization.
- Individuals with specific mental health conditions, including schizophrenia, bipolar disorder, or major depressive disorder.
- Those currently accessing secondary or tertiary mental health and addiction services.
For those who do not meet these criteria, the cost of the funded vaccine (if purchased privately) typically ranges between $25 and $40 at most pharmacies, while enhanced vaccines like Fluad may cost around $50.
Appointments can be managed through the “Book My Vaccine” system, via a GP, or at local pharmacies. Health officials recommend a 15-minute waiting period after the injection to monitor for rare allergic reactions. While mild side effects—such as a low-grade fever or soreness at the injection site—are common, they are signs that the immune system is responding to the vaccine.
The Broader Respiratory Landscape
The fight against the flu is now part of a larger, more complex strategy to manage “tripledemic” risks involving influenza, COVID-19, and RSV. Professor Peter McIntyre, Head of Department of Paediatrics and Child Health at the University of Otago, notes that COVID-19 is now a year-round presence, which has disrupted the traditional seasonal peaks of other viruses.
Because of this overlap, medical advisors suggest a “bundled” approach to immunization. If you are in a high-risk category, it is often sensible to receive an updated COVID-19 booster at the same time as your flu shot to ensure maximum protection during the winter months.
Looking ahead, the medical community is awaiting the arrival of nasal spray flu vaccines, which are currently in development. These would eliminate the need for needles, potentially increasing uptake among children and those with needle phobias.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare provider to determine the best vaccination schedule for your specific health needs.
Health authorities will continue to monitor the spread of the H3N2 Subclade K variant through the end of the immunisation programme on December 31. Updated surveillance data on vaccine effectiveness will likely be released following the conclusion of the winter peak.
Do you have questions about this year’s flu strains? Share your thoughts in the comments or share this guide with someone who may be eligible for a free vaccine.
